These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2892030)

  • 1. Bismuth/ofloxacin combination for duodenal ulcer.
    Bayerdörffer E; Simon T; Bästlein C; Ottenjann R; Kasper G
    Lancet; 1987 Dec; 2(8573):1467-8. PubMed ID: 2892030
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of bismuth subsalicylate versus cimetidine on Campylobacter pylori, ulcer healing and rate of recurrence].
    Eberhardt R; Kasper G; Dettmer A; Höchter W; Hagena D
    Med Klin (Munich); 1988 May; 83(12):402-5. PubMed ID: 3043160
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ofloxacin in the therapy of Campylobacter pylori-positive duodenal ulcer. A prospective controlled randomized study].
    Bayerdörffer E; Kasper G; Pirlet T; Sommer A; Ottenjann R
    Dtsch Med Wochenschr; 1987 Sep; 112(37):1407-11. PubMed ID: 3304929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of recurrence with bismuth subsalicylate in a patient with recurrent and H2 receptor antagonist refractory duodenal ulcer].
    Bayerdörffer E; Mannes GA; Pfaller P; Sauerbruch T
    Internist (Berl); 1989 Jun; 30(6):390-2. PubMed ID: 2668217
    [No Abstract]   [Full Text] [Related]  

  • 5. [Morphologic change in Campylobacter pylori associated gastritis in and following successful antibacterial therapy].
    Rühl GH; Börsch G
    Pathologe; 1989 Jan; 10(1):64-5. PubMed ID: 2922381
    [No Abstract]   [Full Text] [Related]  

  • 6. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract]   [Full Text] [Related]  

  • 7. Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
    Maniatis AG; Brazer SR
    Am J Gastroenterol; 1994 Jun; 89(6):947-8. PubMed ID: 8198114
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dose-effect studies with bismuth salts for the elimination of Campylobacter pylori].
    Menge H; Hofmann J; Gregor M
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():44-6. PubMed ID: 3318192
    [No Abstract]   [Full Text] [Related]  

  • 10. [Ofloxacin in therapy of "resistant" duodenal ulcer. A pilot study].
    Bayerdörffer E; Pirlet T; Sommer A; Kasper G; Ottenjann R
    Z Gastroenterol; 1988 Mar; 26(3):155-9. PubMed ID: 2900584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
    Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
    Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cure of duodenal ulcer associated with eradication of Helicobacter pylori.
    Rauws EA; Tytgat GN
    Lancet; 1990 May; 335(8700):1233-5. PubMed ID: 1971318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined drug therapy against Campylobacter in duodenal ulcer and non-ulcerous dyspepsia].
    Tyszkiewicz T
    Lakartidningen; 1989 Mar; 86(10):843. PubMed ID: 2921896
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current insights in the pathogenesis and treatment of duodenal ulcer].
    Beker JA; Koek GH
    Ned Tijdschr Geneeskd; 1991 Jan; 135(3):107-8. PubMed ID: 1996162
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic chemotherapy for Helicobacter pylori eradication?
    Islam S; McLean AJ
    Gut; 1990 Dec; 31(12):1421-2. PubMed ID: 2265791
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo susceptibility of Campylobacter pylori.
    Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH
    Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with colloidal bismuth subcitrate in duodenal ulcer disease.
    Bianchi Porro G; Lazzaroni M; Cortvriendt WR
    Digestion; 1987; 37 Suppl 2():47-52. PubMed ID: 3305118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].
    Labenz J; Gyenes E; Rühl GH; Börsch G
    Med Klin (Munich); 1993 May; 88(5):297-9. PubMed ID: 8326916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of a combination of colloidal bismuth and pirenzepine in duodenal ulcer in non-responders to anti-H2 receptors].
    Manca A; Ferraris R; Ghezzo L; Asnaghi G; Ferro GF
    Minerva Dietol Gastroenterol; 1988; 34(2):135-8. PubMed ID: 3173756
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination treatment: colloidal bismuth subcitrate with H2-antagonists.
    Salmon PR
    Digestion; 1987; 37 Suppl 2():42-6. PubMed ID: 2887475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.